Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 02 2023
Historique:
entrez: 15 2 2023
pubmed: 16 2 2023
medline: 18 2 2023
Statut: epublish

Résumé

With the ongoing COVID-19 pandemic, it is crucial to assess the current burden of disease of community-acquired SARS-CoV-2 Omicron variant in hospitalized patients to tailor appropriate public health policies. Comparisons with better-known seasonal influenza infections may facilitate such decisions. To compare the in-hospital outcomes of patients hospitalized with the SARS-CoV-2 Omicron variant with patients with influenza. This cohort study was based on a national COVID-19 and influenza registry. Hospitalized patients aged 18 years and older with community-acquired SARS-CoV-2 Omicron variant infection who were admitted between January 15 and March 15, 2022 (when B.1.1.529 Omicron predominance was >95%), and hospitalized patients with influenza A or B infection from January 1, 2018, to March 15, 2022, where included. Patients without a study outcome by August 30, 2022, were censored. The study was conducted at 15 hospitals in Switzerland. Community-acquired SARS-CoV-2 Omicron variant vs community-acquired seasonal influenza A or B. Primary and secondary outcomes were defined as in-hospital mortality and admission to the intensive care unit (ICU) for patients with the SARS-CoV-2 Omicron variant or influenza. Cox regression (cause-specific and Fine-Gray subdistribution hazard models) was used to account for time-dependency and competing events, with inverse probability weighting to adjust for confounders with right-censoring at day 30. Of 5212 patients included from 15 hospitals, 3066 (58.8%) had SARS-CoV-2 Omicron variant infection in 14 centers and 2146 patients (41.2%) had influenza A or B in 14 centers. Of patients with the SARS-CoV-2 Omicron variant, 1485 (48.4%) were female, while 1113 patients with influenza (51.9%) were female (P = .02). Patients with the SARS-CoV-2 Omicron variant were younger (median [IQR] age, 71 [53-82] years) than those with influenza (median [IQR] age, 74 [59-83] years; P < .001). Overall, 214 patients with the SARS-CoV-2 Omicron variant (7.0%) died during hospitalization vs 95 patients with influenza (4.4%; P < .001). The final adjusted subdistribution hazard ratio (sdHR) for in-hospital death for SARS-CoV-2 Omicron variant vs influenza was 1.54 (95% CI, 1.18-2.01; P = .002). Overall, 250 patients with the SARS-CoV-2 Omicron variant (8.6%) vs 169 patients with influenza (8.3%) were admitted to the ICU (P = .79). After adjustment, the SARS-CoV-2 Omicron variant was not significantly associated with increased ICU admission vs influenza (sdHR, 1.08; 95% CI, 0.88-1.32; P = .50). The data from this prospective, multicenter cohort study suggest a significantly increased risk of in-hospital mortality for patients with the SARS-CoV-2 Omicron variant vs those with influenza, while ICU admission rates were similar.

Identifiants

pubmed: 36790812
pii: 2801464
doi: 10.1001/jamanetworkopen.2022.55599
pmc: PMC9932839
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2255599

Investigateurs

Sarah Tschudin-Sutter (S)
Ulrich Heininger (U)
Philipp Jent (P)
Michael Büttcher (M)
Yvonne Nussbaumer (Y)
Danielle Vuichard Gysin (D)
Christoph Berger (C)
Domenica Flury (D)
Marie-Céline Zanella Terrier (MC)

Références

Euro Surveill. 2022 Jan;27(4):
pubmed: 35086614
Emerg Microbes Infect. 2022 Dec;11(1):1742-1750
pubmed: 35730665
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Med. 2022 Sep;28(9):1933-1943
pubmed: 35675841
Int J Infect Dis. 2021 Feb;103:316-322
pubmed: 33279652
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Lancet Infect Dis. 2021 Nov;21(11):1507-1517
pubmed: 34171231
Lancet Reg Health West Pac. 2022 Mar;20:100365
pubmed: 35005672
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Euro Surveill. 2022 Jan;27(1):
pubmed: 34991775
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
J Intensive Care. 2020 Sep 14;8:70
pubmed: 32939266
Emerg Med Pract. 2021 Feb 01;23(Suppl 2):CD1-CD2
pubmed: 33529515

Auteurs

Lea Portmann (L)

Department of Health Sciences and Medicine, Clinic St Anna, University of Lucerne, Lucerne, Switzerland.

Marlieke E A de Kraker (MEA)

Geneva University Hospitals and Faculty of Medicine, Infection Control Program and WHO Collaborating Center, Geneva, Switzerland.

Georg Fröhlich (G)

Heart Clinic Lucerne, Lucerne, Switzerland.
Charité-Universitätsmedizin Berlin, Berlin, Germany.

Amaury Thiabaud (A)

Institute of Global Health of the University of Geneva, Geneva, Switzerland.

Maroussia Roelens (M)

Institute of Global Health of the University of Geneva, Geneva, Switzerland.

Peter W Schreiber (PW)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.

Nicolas Troillet (N)

Department for Infectious Diseases, Central Institution, Valais Hospital, Sion, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.

Anne Iten (A)

Geneva University Hospitals and Faculty of Medicine, Infection Control Program and WHO Collaborating Center, Geneva, Switzerland.

Andreas Widmer (A)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department for Infectious Diseases, University Hospital Basel, Basel, Switzerland.

Stephan Harbarth (S)

Geneva University Hospitals and Faculty of Medicine, Infection Control Program and WHO Collaborating Center, Geneva, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.

Rami Sommerstein (R)

Department of Health Sciences and Medicine, Clinic St Anna, University of Lucerne, Lucerne, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH